D-glycero-beta-D-galacto-2-Nonulopyranosonic acid, 5-(acetylamino)-3,5-dideoxy-, monopotassium salt | 103882-92-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-glycero-beta-D-galacto-2-Nonulopyranosonic acid, 5-(acetylamino)-3,5-dideoxy-, monopotassium salt
• 英文别名: potassium;(2S,4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylate
• CAS: 103882-92-4
• 化学式: C11H18KNO9
• 分子量: 347.36
• InChiKey: LHXZKRNKFQCJFJ-BKSOAOGQSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -8.2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  180
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  N-acetyl neuraminic acid 生成 D-glycero-beta-D-galacto-2-Nonulopyranosonic acid, 5-(acetylamino)-3,5-dideoxy-, monopotassium salt
  参考文献：
  名称：

  KIBOSI, NOBUYUKI;KOMATSU, JOSITOMO;OGASAVARA, SADANORI

  摘要：

  DOI：

文献信息

• Use of N-acetylneuraminic-acid salts for the preparation of a medicament for decongesting nasal mucous membranes
  申请人：MECT CORPORATION

  公开号：EP0296620A2

  公开（公告）日：1988-12-28

  A repairing agent for cells and tissues is disclosed, which agent comprises, as an active ingredient, a compound of the general formula: wherein Z represents lithium, potassium, sodium, ammonium or an organic ammonium when n is 1, and Z represents calcium, barium or magnesium when n is 2.

  本发明公开了一种细胞和组织修复剂，其活性成分包括通式如下的化合物： 其中，当 n 为 1 时，Z 代表锂、钾、钠、铵或有机铵；当 n 为 2 时，Z 代表钙、钡或镁。
• Preparation for treating systemic lupus erythematosus
  申请人：MECT CORPORATION

  公开号：EP0386657A1

  公开（公告）日：1990-09-12

  An preparation for treating systemic lupus erythematosus containing the following compound: wherein, when n is 1, Z represents a hydrogen, lithium, potassium, sodium, ammonium or organic ammonium, and when n is 2, Z represents calcium, barium or magnesium, as an active ingredient and pharamacologically permittable carrier. The preparation of the present invention may be used in any administration method such as hypodermic, intramuscular and intravenous.

  一种治疗系统性红斑狼疮的制剂，含有以下化合物： 其中，当 n 为 1 时，Z 代表氢、锂、钾、钠、铵或有机铵；当 n 为 2 时，Z 代表钙、钡或镁、 作为活性成分和药理学允许的载体。本发明制剂可用于皮下注射、肌肉注射和静脉注射等任何给药方法。
• Preparation for treating renal disease
  申请人：MECT CORPORATION

  公开号：EP0473108A2

  公开（公告）日：1992-03-04

  A preparation for treating renal disease, such as nephiritis, which comprises, an effective amount of N-acetylneuraminic acid shown by the formula: wherein, when n is 1, Z represents hydrogen, lithium, potassium, sodium, ammonium or oraganic ammonium, and, when n is 2, Z represents calcium, barium or magnesium; and, a pharmacologically acceptable carrier.

  一种治疗肾脏疾病（如肾炎）的制剂，它包括有效量的 N-乙酰神经氨酸，如式所示： 其中，当 n 为 1 时，Z 代表氢、锂、钾、钠、铵或高甘铵；当 n 为 2 时，Z 代表钙、钡或镁；以及药理学上可接受的载体。
• Process for producing novel sialo-sugar chain
  申请人：WAKAYAMA UNIVERSITY

  公开号：US10975346B2

  公开（公告）日：2021-04-13

  The present invention provides a novel sialo-sugar chain, a process for producing the sialo-sugar chain, and a device for producing the sialo-sugar chain. A sialo-sugar chain can be easily and efficiently mass-produced by reacting a sugar wherein a hydroxy groups is substituted with an alkynyl group (herein sometimes referred to as “alkynylated sugar”) with a specific sialic acid donor in the presence of a sialic acid-introducing enzyme.

  本发明提供了一种新型硅糖链、一种生产硅糖链的工艺和一种生产硅糖链的装置。通过使羟基被炔基取代的糖（此处有时称为 "炔化糖"）与特定的硅酸供体在硅酸导入酶的存在下发生反应，可以方便、高效地大量生产硅酸糖链。
• PROCESS FOR PRODUCING NOVEL SIALO-SUGAR CHAIN
  申请人：Wakayama University

  公开号：EP2759548B1

  公开（公告）日：2016-09-07